Nightfood Holdings (OTCQB: NGTF), operating through its TechForce Robotics subsidiary, has announced progress in Phase 2 of its joint development collaboration with Oncotelic Therapeutics (OTCQB: OTLC), marked by the deployment of PUR-E, an autonomous clean room support robot, within SAPU Bio’s OEB-5 sterile injectable cGMP facility. This deployment extends the initiative beyond Phase 1 materials logistics into sterile manufacturing and clean room environments, where TechForce and Oncotelic are evaluating robotics, automation, and AI-driven technologies to support regulated pharmaceutical workflows.
PUR-E joins TechForce’s LIM-E autonomous GMP support robot at the SAPU Bio facility. The systems are being used to assess opportunities in sterile manufacturing operations, electronic batch record processes, and other cGMP activities. According to the companies, this initiative is part of a broader effort to develop robotics and automation solutions for pharmaceutical manufacturing, biotechnology, and life sciences environments. PUR-E operates as part of TechForce’s Robotics-as-a-Service Provider (RaaSP) platform, which offers flexible, scalable automation solutions to customers while generating recurring revenue opportunities.
The collaboration highlights the growing importance of automation in pharmaceutical manufacturing, where precision, consistency, and contamination control are critical. By integrating robotics into clean rooms, the companies aim to improve operational efficiency, workflow consistency, labor optimization, and scalability. The full press release detailing this advancement is available at https://ibn.fm/mXU1p.
Nightfood Holdings, doing business as TechForce Robotics, is an AI-enhanced robotics and automation company focused on developing, integrating, deploying, and commercializing intelligent automation solutions across multiple industries. Through its TechForce Robotics platform, the company develops and deploys autonomous robotic systems designed to improve operational efficiency, workflow consistency, labor optimization, and scalability across hospitality, foodservice, commercial, laboratory, pharmaceutical, and emerging enterprise automation environments. The company operates through a vertically integrated business model that combines proprietary robotics technology, AI-enhanced software, real-world operating environments, strategic manufacturing partnerships, and scalable deployment infrastructure. By integrating advanced robotics, machine vision, intelligent automation, and data-driven operational insights, TechForce Robotics seeks to address growing labor challenges and productivity demands across a wide range of industries.
Nightfood Holdings delivers its solutions through a Robotics-as-a-Service (RaaS) model, providing customers with flexible, scalable automation solutions while generating recurring revenue opportunities. As the company expands into pharmaceutical automation, laboratory automation, industrial automation, and other high-precision applications, it continues to leverage strategic partnerships and advanced engineering capabilities to accelerate innovation and commercialization across multiple high-growth markets. More news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF.
This announcement underscores the increasing convergence of robotics and pharmaceutical manufacturing, a trend that could significantly enhance production efficiency and quality control in regulated environments. The successful deployment of PUR-E in a sterile injectable facility demonstrates the potential for autonomous systems to operate in highly controlled settings, paving the way for broader adoption across the pharmaceutical industry.
